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Background: Patients receiving maintenance haemodialysis (HD) are at higher risk for acquiring Hepatitis B Virus
(HBV) and Hepatitis C Virus (HCV) infections than the general population. Strict infection control measures are
essential to prevent nosocomial transmission. We aimed to investigate the incidence and prevalence of HBV and
HCV infection in the HD population of Libya as well as risk factors for infection.
Methods: All adult patients receiving maintenance HD (n=2382) in Libyan dialysis centres (n=39) were studied
between May 2009 and October 2010. Testing for Hepatitis B surface antigen (HBsAg) and anti-HCV antibodies was
performed at initiation of dialysis and every 3–6 months thereafter. Patients who were sero-negative for HBV and
HCV (n=1160) were followed up for 1 year to detect sero-conversions.
Results: Participant median age was 49 years and 58% were male. 831 patients (34.9%) were sero-positive for HBV
and/or HCV (anti-HCV positive 31.1%; HBsAg positive 2.6%; both positive 1.2%). Of the sero-positive patients
4.7% were known to be infected before the initiation of HD. The prevalence of HBV±HCV infection varied widely
between HD centres from 0% to 75.9%. Sero-positive patients were younger, had longer time on dialysis and more
previous blood transfusions. Prospective follow-up revealed an incidence of sero-conversion of 7.7% during 1 year
(7.1% HCV; 0.6% HBV). Wide variation in rates of newly acquired infections was observed between dialysis centres.
All new HBV cases were referred from centres already treating HBV infected patients. New HCV infections were
reported in most centres but the rate of HCV sero-conversion varied widely from 1.5% to 31%. Duration of dialysis,
history of previous renal transplant and history of receiving HD in another centre in Libya were significantly
associated with sero-conversion.
Conclusion: Patients on maintenance HD in Libya have a high incidence and prevalence of HCV infection and
lower rates of HBV infection. The factors associated with HBV and HCV infection are highly suggestive of
nosocomial transmission within HD units. Urgent action is required to improve infection control measures in HD
centres and to reduce dependence on blood transfusions for the treatment of anaemia.
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Chronic infections with Hepatitis B Virus (HBV) and
Hepatitis C Virus (HCV) are associated with serious
health risks due to hepatic cirrhosis and hepatocellular
carcinoma. Patients receiving maintenance haemodialy-
sis (HD) therapy are at increased risk for acquiring these
infections and have a higher prevalence of HBV and
HCV than the general population [1,2]. Prior to effective
screening of blood donations, HCV infection was asso-
ciated with blood transfusions needed to correct the an-
aemia associated with kidney disease [3,4] but patient to
patient transmission in HD units is also reported [5,6].
HBV infection is usually due to patient to patient trans-
mission within HD units [7]. Recognition of the risk of
nosocomial infection has resulted in recommendations
that strict infection control procedures should be fol-
lowed on HD units; patients with blood-bourne virus
infections should be isolated from sero-negative patients
during dialysis and patients as well as staff should be
vaccinated against hepatitis B [8,9]. The introduction of
blood donor screening and a reduction in blood trans-
fusions due to the availability of recombinant erythro-
poietin has significantly reduced the incidence of new
HCV infections among HD patients in many countries
[10-12].
Libya provides free access to maintenance HD for end
stage kidney disease through a rapidly expanding net-
work of centres. Although there are no national dialysis
practice guidelines or infection control polices enforced
by health care authorities, there is general agreement
that patients on HD should be screened for HBV and
HCV infection before the initiation of HD and moni-
tored every 3–6 months thereafter [13]. Sero-positive
patients are dialysed on dedicated machines either in an0
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Figure 1 Prevalence of HBV and/or HCV sero-positivity in different haisolated area or alongside sero-negative patients if space
does not allow isolation [13]. A national serological sur-
vey for HBV and HCV infections among the general
population was performed in Libya during 2003 and
revealed prevalences of 2.2% and 1.2% for HBV and
HCV, respectively [14]. Other local surveys reported that
the rate of HBsAg positivity among blood donors ranged
from 1.3% to 4.6% [15], while the rate of HCV antibodies
was 1.2% [16]. Global data indicate that the prevalence
of HBV and HCV infection is high in populations of Af-
rica and the Middle Eastern regions [17-19]. HCV infec-
tion was estimated by World Health Organisation to
affect 4.6% of the Eastern Mediterranean population and
5.3% of the population of Africa [20].This study aimed
to investigate for the first time the incidence and preva-
lence of HBV and HCV infection in the entire HD popu-
lation of Libya.
Results
The median age of adult HD patients included was 49
years (range 36–61 years) and 58% were male. A total of
831 patients (34.9%) were sero-positive for HBV and/or
HCV. The majority of infected patients were positive for
anti-HCV antibodies (31.1%) and 2.6% were HBsAg posi-
tive. Twenty-eight patients (1.2%) had mixed infection
with HBV and HCV (Additional file 1: Table S1). Of the
sero-positive patients 4.7% were known to be infected
before the initiation of HD. Overall the prevalence of
sero-positivity was similar among males and females
(35.8% versus 33.7%, respectively) but males comprised a
greater proportion of those with HBV or combined in-
fection (Additional file 1: Table S1; P=0.01 for compari-
son between groups). Hepatitis B vaccine had been
administered in 1216 of 1520 patients but antibodyis Units
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status was not documented in 862 patients.
The prevalence of HBV and/or HCV infection varied
widely between HD centres from 0% to 75.9%. Four cen-
tres had no sero-positive patients and half of centres
were free from HBV infection. Patients sero-positive for
both viruses were found in 28.2% of centres (Figure 1).
Univariate analysis of potential risk factors for infection
with HBV and/or HCV was performed by comparing
infected and non-infected patients (Table 1). Sero-
positive patients were younger and had been receiving
dialysis for substantially longer. History and number of
blood transfusions was also significantly associated with
sero-positivity. Mean values for Alanine Aminotransfer-
ase and Aspartate Aminotransferase were higher in sero-
positive patients despite being within the normal range.
Results of the prospective study showed that 89 of
1160 previously sero-negative patients sero-converted
during 1 year (incidence 7.7%). The majority (82 patients)
developed anti-HCV antibodies (incidence 7.1%). Seven
patients became positive for HBsAg (incidence 0.6%). Of
these one had previously been vaccinated against hepa-
titis B, four had not been vaccinated and in two vaccin-
ation status was not documented. Age and gender
distribution of those who sero-converted is shown in
Additional file 2: Table S2.
Figure 2 shows wide variation in rates of newly
acquired infections between different dialysis centres.
No sero-conversion was found in two small-capacity
centres (one treating 2 patients and the other, 5
patients). New HBsAg positive cases were detected in 4
centres in 3.3-10.3% of previously negative patients. AllTable 1 Factors potentially associated with HBV and/or HCV i
Factors potentially associated with HBV±HCV infection Sero-
Numb
Age in years (mean± SD) 831
Males (number and percent) 831
Whites (number and percent) 805
Dialysis vintage in years (median and IQR) 831
Previous blood transfusion (number and percent) 597
Number of blood transfusions (median and IQR) 597
Previous renal transplant (number and percent) 822
Previous dialysis abroad (number and percent) 617
Previous dialysis in another Libyan centre (number and percent) 612
Haemoglobin level in g/dl (mean± SD) 831
Alanine Aminotransferase in IU/L (mean± SD) 269
Aspartate Aminotransferase in IU/L (mean± SD) 232
Diabetes (number and percent) 831
Erythropoietin treatment (number and percent) 604
*Number of patients with valid data for each variable.new HBV cases were referred from centres already treat-
ing HBV infected patients. New HCV infections were
reported in most centres (33 of 35) but the rate of HCV
sero-conversion varied widely from 1.5% to 31% of
patients. Most of the centres with HCV sero-conversions
(31/33) were providing HD treatment to previously
HCV-infected patients. However, anti-HCV antibodies
were discovered in 9 patients (31%) in a centre which
was previously treating exclusively sero-negative patients
(coded CG). Two other HCV sero-conversions occurred
in another previously sero-negative HD centre (coded BE).
There were no correlations between number of HD
patients treated in each centre and the prevalence or in-
cidence of sero-positivity to HBV or HCV. There was no
difference in prevalence or incidence of HBV or HCV
infection between units that: routinely practiced isola-
tion of sero-positive patients versus those that did not;
units with hand washing facilities in each cubicle versus
not and units that had adequate facilities for sharps dis-
posal versus not.
Analysis of possible risk factors for new HBV or HCV
infections is shown in Table 2. Only duration of dialysis,
history of previous renal transplant and history of receiv-
ing HD in another centre in Libya were significantly dif-
ferent between patients who sero-converted and those
who remained sero-negative.
Discussion
The prevalence of anti-HCV antibodies in patients re-
ceiving HD (31.1%) was remarkably high and is approxi-
mately 25 times higher than in the general population
[14]. It is also higher than the prevalence of 20.5%nfection in haemodialysis centres in Libya
positive N=831 Sero-negative N=1551 P- value
er* Value Number* Value
47.1±14.4 1551 49.5±16.2 <0.001
494 (59.4%) 1551 887 (57.2%) 0.296
718 (89.2%) 1528 1312 (85.9%) 0.023
6 (3–10) 1551 2 (0.1-3) <0.001
482 (80.7%) 1010 688 (68.1%) <0.001
2 (1–3) 1010 1 (0–3) <0.001
115 (14.0%) 1533 41 (2.7%) <0.001
376 (60.9%) 1025 540 (52.7%) 0.001
324 (52.9%) 1018 447 (43.9%) <0.001
10.2±1.9 1551 9.7±1.8 <0.001
27.8±20.2 353 19.6±17.9 <0.001
29.6±21.1 328 21.3±20.3 <0.001
195 (23.5%) 1551 551 (35.5%) <0.001
450 (74.5%) 1059 830 (78.4%) 0.071
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Figure 2 Incidence of new HBV or HCV infections in haemodialysis patients during a 1-year follow up period.
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2001 in Libya [16]. Globally the prevalence of HCV
among patients receiving HD varies from as low as 6.1%
in Germany [21] to as high as 76% in Casablanca [22].
In general, North Africa and the Middle East are high
prevalence areas both in the general population and in
HD patients [20]. Previous studies from the region have
reported a prevalence of anti-HCV antibodies in HD
patients of 50% in Saudi Arabia [23], 42% in Tunisia
[24], 20.2% in Turkey [25] and 21% in Jordan [26]. In
contrast, the observed prevalence of HBV infection
(2.6%) is similar to the general population and similar toTable 2 Factors potentially associated with new HBV or HCV
Factors potentially associated with new HBV±HCV infection
Num
Age in years (mean± SD) 89
Males (number and percent) 89
Whites (number and percent) 89
Dialysis vintage in years (mean± SD) 89
Previous blood transfusion (number and percent) 45
Number of blood transfusions (mean± SD) 45
Previous renal transplant (number and percent) 89
Previous dialysis abroad (number and percent) 48
Previous dialysis in another Libyan centre (number and percent) 48
Haemoglobin level in g/dl (mean± SD) 89
Alanine Aminotransferase in IU/L (mean± SD) 27
Aspartate Aminotransferase in IU/L (mean± SD) 24
Diabetes (number and percent) 89
Erythropoietin treatment (number and percent) 51that reported in HD patients in other regions including
Europe (4.1%), Japan (2.2%) and the USA (2.4%) [27]. A
study sample from the Dialysis Outcome and Practice
Patterns Study that included 8615 adult HD patients
from 308 dialysis facilities in Western Europe and the
United States, reported prevalence rates for HBV infec-
tion ranging from 0% to 6.6% [28]. Studies from less
developed countries estimated that the proportion of
HBsAg carriers in the HD population varies from 2% to
20% [29-32]. According to the 2008 Saudi Centre for
Organ Transplantation (SCOT) report, HBV sero-
positivity was 4.6% in the Saudi HD population [33]infection in HD centres
Sero-converted Stayed sero-negative P- value
N=89 N=1071
ber* Value Number* Value
50.9±15.8 1071 50±16.6 0.635
54(60.7%) 1071 613(57.2%) 0.528
75 (84.3%) 1056 927 (87.8%) 0.335
4.1±4.4 1071 2.2±2.6 0.001
34 (75.6%) 716 481(67.2%) 0.244
3.6±6.9 716 1.8±2.6 0.083
6 (6.7%) 1064 28 (2.6%) 0.028
27 (56.3%) 714 395 (55.3%) 0.900
31 (64.6%) 707 371(52.5%) 0.023
9.9±2.1 1071 9.6±1.8 0.220
21.9±22.7 274 18.6±17.8 0.272
23±23.8 252 20.8±21.2 0.925
35 (39.3%) 1071 385 (35.9%) 0.524
7 (13.7%) 729 100 (13.7%) 0.999
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general, the prevalence and incidence of HBV and HCV
infections in HD patients reflects the prevalence of these
infections in the general population, the quality of
healthcare services in a community and the standards of
infection control practices in HD units. The importance
of HBV and HCV as a health risk in patients on HD is
illustrated by our observation that 3% of deaths in
Libyan HD patients during a 1 year observation period
were due to liver failure and that 13 of the 14 patients
who died of liver failure were sero-positive for HCV
and/or HBV [35].
Our data show that sero-positive patients were signifi-
cantly younger on average than sero-negative patients.
This observation is in agreement with a previous report
from Libya showing that the highest prevalence of HCV
antibodies was observed in HD patients aged 36–55
years [16]. Other studies [28,36,37] have reported a
higher prevalence of HBV or HCV sero-positivity in
older patients and the reason for this difference in not
clear. On the other hand, the prevalence and incidence
of HBV or HCV sero-positivity was significantly related
to the length of time on HD. This is consistent with
nosocomial transmission related to dialysis since longer
duration of dialysis represents a longer period at risk of
acquiring an infection. Similar observations have been
reported by other authors [38-41]. Prevention of nosoco-
mial transmission is of vital importance in Libya as HCV
antiviral treatment is expensive and its availability is lim-
ited to only a few centres.
A positive history of blood transfusions as well as the
number of blood transfusions was strongly associated
with HBV or HCV infection at baseline, but not with
new infections. Prior to the introduction of effective
screening of blood donors, blood transfusions were
recognised as the leading source of HCV infection and
some of these infections may have been acquired before
adequate screening was introduced [21,40]. In addition it
is possible that some blood donors with HCV infection
are being missed by current screening procedures and
these may need to be reassessed [42,43]. On the other
hand the lack of association between blood transfusions
and new infections suggests that fewer infections are
acquired by this route than previously. A large propor-
tion of patients had previously received blood transfu-
sions. The risk of infection could therefore be further
reduced by more effective management of anaemia with
iron supplementation and erythropoietin. In accordance
with other studies [41,44,45], HBV or HCV infection
was more prevalent in patients with a history of previous
renal transplant. Infection in these patients might have
been transmitted from an infected donor kidney or
blood transfused peri-operatively. This observation
emphasizes the need for adequate screening of potentialkidney donors, which is deficient in some countries. The
shortage of donated kidneys in Libya induces many
patients to seek a transplant abroad.
Another concern raised by the current study is that
HBV or HCV infection was associated with a history of
HD in another centre either in Libya or abroad. Many
patients travel for social reasons but some also transfer
to a maintenance HD centre after initiating dialysis as
an emergency in a specialised centre providing acute ser-
vices or may travel to another centre for surgery to cre-
ate an arteriovenous fistula [13]. The association of
hepatitis virus infection with travel suggests that the risk
of nosocomial infection varies between dialysis centres
within Libya and abroad. The former is confirmed by
our data showing a marked variation in both prevalence
and incidence of HBV and HCV infection among Libyan
HD units (Figures 1 and 2). These observations
emphasize the importance of isolating patients following
their return and monitoring them for sero-conversion.
Prospective follow up of sero-negative HD patients
enabled us to verify 89 sero-conversions for HBV or
HCV during 1 year, giving an overall incidence of 7.7%
for new infections. The incidence rate of 0.6% for HBsAg
sero-conversion is similar to that reported in Europe,
Japan and the USA (0.4-1.8 per 100 patient-years) [28].
Three new HBsAg positive patients were detected in a
single centre that was treating 20 other HBsAg positive
patients and 2 new cases were detected in another
centre that was treating 14 HBsAg positive patients, sug-
gesting that nosocomial transmission probably occurred.
We observed a high incidence of new HCV infections
during the 1-year observation period (7.2%). The
reported incidence of new HCV infections varies consid-
erably between countries. A rate as low as 0.4% was
observed in France from 1997 to 2000 [46] but higher
rates have been reported from the Mediterranean region.
According to the 2008 SCOT report, the annual rate of
HCV sero-conversion in Saudi HD patients was 7-9%
[33] while in Jordan it was 2.6% [26]. In our study most
new cases were observed in centres treating other
patients with HCV infection, suggesting nosocomial
transmission. Interestingly 9 new HCV infections were
observed in one unit and 2 in another that previously
accepted only patients without HCV infection. This
raises the possibility of transmission from a carrier that
was not detected by current screening procedures.
A striking observation from this study is the wide vari-
ation in incidence and prevalence of HBV and HCV
infections among different HD units (Figures 1 and 2).
Interestingly none of the potential centre-related factors
that we assessed formally explained this variation. On
the other hand, we observed variations in other practices
that may be relevant. Most facilities faced a problem of
increasing number of patients and most of them
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space and staff. Infection control precautions also varied
widely between centres. They were strictly enforced in
some places but frequently breached in others. This
seemed to depend on staff initiative rather than national
guidelines. On the other hand, dialyser reuse was not
permitted and all bloodlines as well as other consum-
ables were disposed after a single use [13]. Some brands
of HD machines were equipped with a sphygmomanom-
eter. Otherwise, most non- disposable instruments used
in HD environment were shared between sero-positive
and sero-negative patients. The use of multi-dose vials
of heparin was common and is likely to have been an
important cause of nosocomial infections. Many patients
started HD without being vaccinated against HBV. Even
in vaccinated patients the antibody titre was not
assessed. The wide variation in HBV and HCV preva-
lence and incidence between dialysis centres implies that
there is potential to reduce blood-borne virus infection
by transferring best practice from HD centres with low
infection rates. In particular infection control procedures
should be investigated in centres with high infection
rates and the use of multidose heparin vials must be
stopped urgently. Previous studies from the region show
that with appropriate intervention HCV infection rates
in HD centres may be substantially improved. For ex-
ample in Iran, HCV prevalence reduced from 14.4% in
1999 to 4.5% in 2006 [47] and in Saudi Arabia from
2.4% in 2001 to 0.2% in 2005 [48].
Several limitations of this study should be conceded.
Medical records were often incomplete and additional
clinical information was frequently obtained by inter-
viewing staff and patients. Serological testing was done
in local laboratories and it is likely that there was some
variation in the quality of testing. Data regarding hepa-
titis B core antibodies (HBcAb) or hepatitis B DNA were
not available. In one recent study of haemodialysis
patients in Egypt who were negative for HBsAg, hepatitis
B DNA was detected in 4.1% and HBcAb in 20% [49]. It
is therefore possible that we failed to detect cases of oc-
cult hepatitis B infection. Testing for HCV relied on a
third generation ELISA to detect anti-HCV antibodies
and confirmation or genotyping with PCR is currently
not available in most centres.
Conclusion
In conclusion, patients on maintenance HD in Libya
have a high incidence and prevalence of HCV infection
and lower rates of HBV infection. The factors associated
with HBV and HCV infection are highly suggestive of
nosocomial transmission within HD units. Urgent action
is required to improve infection control measures in HD
centres and to reduce dependence on blood transfusions
for the treatment of anaemia. The data presented wereobtained before the recent conflict in Libya. It is possible
that disruption of services due to the conflict may have
exacerbated the problem of hepatitis virus infection in
HD patients.
Methods
This descriptive study was carried out in all HD centres
treating adult patients in Libya (n=39) from May 2009 to
October 2010. Phase I of the study was a collection of
cross-sectional data regarding all adult patients in main-
tenance HD facilities (n=2382). Large and medium cap-
acity HD facilities were visited by the researchers in
order to collect data. Patient records were used to obtain
patients’ age, gender, time on HD, medical history, sero-
positivity to HBV and HCV as well as other laboratory
results. Sero-positivity to HBV was defined by detection
of hepatitis B surface antigen (HBsAg) and sero-
positivity to HCV by detection of anti-HCV antibodies
by a third generation enzyme linked immunoassay
(ELISA). ELISA tests were performed in local laborator-
ies. In addition, 1732 patients from 24 centres were
interviewed regarding other potential risk factors for
HBV and HCV infection. These included history of
blood transfusions and history of HD in another centre
within Libya or abroad. Data was also obtained regarding
infection control procedures at each HD facility. For
small and remote facilities, data collection forms were
posted to clinical supervisors who were requested to col-
lect information about their patients. They were con-
tacted frequently by phone to deal with any queries
related to the required variables. Forms were returned
within 30 days.
Phase II of the study was to prospectively detect sero-
conversion to HBV or HCV in previously sero-negative
HD patients during 1 year of follow-up. This step
included a cohort of 1160 patients from 35 centres (four
centres were excluded because of incomplete informa-
tion). All sero-conversions were recorded and included
even if patient was transplanted or died afterwards. The
research team frequently monitored HD patients during
the year to assure the inclusion of every new sero-
conversion. All new sero-conversions were retested to
confirm the positive result. Field visits were repeated at
the end of 1 year to validate the information.
Data are presented as mean±SD if normally distributed
or median (interquartile range) if not. Analysis was per-
formed using SPSS version 16.0. A Chi-square test was
used to compare frequencies between groups. Correla-
tions were tested with a Pearson’s test. A t-test was used
to compare means between groups for data with normal
distribution or Mann–Whitney test for non-parametric
data
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